ANURAS Anupam Rasayan India Limited has informed the Exchange about Transcript of the Earnings Call on the Unaudited Financial Results Standalone and Consolidated for the quarter ended June 30, 2025.
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anupam Rasayan India filed the transcript of its Q1 FY26 earnings call. Consolidated revenue grew 91% year-on-year to INR 486 crores, with EBITDA up 118% to INR 129 crores (26.3% margin) and profit after tax surging 297% to INR 49 crores. Standalone revenue rose 93% YoY to INR 316 crores with a 31% EBITDA margin. The company reported an order book of INR 14,646 crores, signed a long-term supply deal with a Japan-based fluorochemicals multinational (for semiconductor and electronics applications) and a letter of intent with European firm E-Lyte Innovations for battery electrolyte solutions. The pharma segment contributed 24% of revenue (3x growth YoY) while performance materials grew 2x to 12% of revenue. The company received INR 277.5 crores from a preferential issue, using INR 175 crores to repay term debt, making it net term debt free, and targets a debt-to-EBITDA ratio of below 2 (pushing towards 1.5).
The strong quarterly results, growing order pipeline, and shift to net term debt free status are positive signals that could support investor confidence and potentially the stock price. However, management declined to disclose the financial value of the new Japanese contract and offered limited visibility on US tariff exposure, which may leave some analyst questions unanswered.